Antibody

76개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved76 programs
AntibodyLimited DatastaleHarbour BioMed (Guangzhou) Co. …Phase 1

pembrolizumab (Keytruda, HBM4003 and pembrolizumab)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#Harbour
Trials 1Status Active
AntibodyLimited DatastaleHanmi Pharmaceutical Company Li…Phase 1

HM95573, cetuximab (HM95573, cetuximab)

Locally Advanced Solid Tumor; Metastatic Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#MetastaticSolidTumor+1
Trials 1Status Active
AntibodyLimited DatastaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Discontinued
AntibodyLimited DatastaleAstraZenecaPhase 1

administered with & without Cetuximab (Irinotecan, Irinotecan (administered with & without Cetuximab))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 1

JS001+Bevacizumab (JS001+Bevacizumab)

Advanced Malignant Solid Tumors · Advanced Malignant Solid Tumors

#AdvancedMalignantSolidTumors#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, KF-0210 (dosage RP2D) + Atezolizumab, dosage RP2D)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-1, KF-0210 (dosage RP2D-1) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleKeythera Pharmaceuticals (Austr…Phase 1

atezolizumab (Tecentriq, KF-0210, dosage RP2D-2, KF-0210 (dosage RP2D-2) + Atezolizumab)

Advanced Solid Tumor; Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#ColorectalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, MCLA-158 + Pembrolizumab)

Advanced/Metastatic Solid Tumors; Colorectal Cancer · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#Antibody#Phase2#monoclonal-antibody#Advanced+3
Trials 1Status Recruiting
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMonopteros Therapeutics Inc.Phase 1

pembrolizumab (Keytruda, MPT-0118 + pembrolizumab)

Solid Tumor, Adult; Advanced Solid Tumor · FRα

#FR#Antibody#Phase1#monoclonal-antibody#SolidTumor+3
Trials 1Status Active
AntibodyLimited DatastalePresage BiosciencesPhase 1

nivolumab (Opdivo, MVC-101 + Nivolumab)

Solid Tumour · Solid Tumour

#SolidTumour#Antibody#Phase1#monoclonal-antibody#Presage
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab (Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RefractoryMetastaticColorectalCa+1
Trials 1Status Recruiting
AntibodyLimited DatastaleGenentech, Inc.Phase 1

MetMAb (MetMAb)

Solid Cancers · Solid Cancers

#SolidCancers#Antibody#Phase1#monoclonal-antibody#Genentech
Trials 1Status Active
AntibodyLimited DatastalePfizerPhase 1

nivolumab (Opdivo, TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Nivolumab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastalePfizerPhase 1

PF-07901800 (TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Rituximab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, TJ033721, TJ033721 (givastomig) , nivolumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#AdvancedCancer+1
Trials 1Status Recruiting

3 / 4 pages

← PreviousNext →